FOLD
Income statement / Annual
Last year (2024), Amicus Therapeutics, Inc.'s total revenue was $528.30 M,
an increase of 32.29% from the previous year.
In 2024, Amicus Therapeutics, Inc.'s net income was -$56.11 M.
See Amicus Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$528.30 M |
$399.36 M |
$329.23 M |
$305.51 M |
$260.89 M |
$182.24 M |
$91.25 M |
$36.93 M |
$4.96 M |
$0.00 |
| Cost of Revenue |
$52.94 M
|
$37.33 M
|
$38.60 M
|
$34.47 M
|
$31.04 M
|
$21.96 M
|
$14.40 M
|
$6.24 M
|
$833,000.00
|
$1.83 M
|
| Gross Profit |
$475.35 M
|
$362.03 M
|
$290.63 M
|
$271.05 M
|
$229.84 M
|
$160.27 M
|
$76.84 M
|
$30.69 M
|
$4.13 M
|
-$1.83 M
|
| Gross Profit Ratio |
0.9
|
0.91
|
0.88
|
0.89
|
0.88
|
0.88
|
0.84
|
0.83
|
0.83
|
0
|
| Research and Development Expenses |
$109.36 M
|
$152.38 M
|
$276.68 M
|
$272.05 M
|
$308.44 M
|
$286.38 M
|
$270.90 M
|
$149.31 M
|
$104.79 M
|
$76.94 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$127.20 M
|
$0.00
|
$71.15 M
|
$47.27 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$323.38 M
|
$275.27 M
|
$213.04 M
|
$192.71 M
|
$156.41 M
|
$169.86 M
|
$127.20 M
|
$88.67 M
|
$71.15 M
|
$47.27 M
|
| Other Expenses |
$17.74 M
|
$0.00
|
$5.34 M
|
$6.21 M
|
$8.85 M
|
$4.78 M
|
-$5.63 M
|
$6.01 M
|
-$4.79 M
|
-$80,000.00
|
| Operating Expenses |
$450.48 M
|
$427.65 M
|
$495.06 M
|
$470.97 M
|
$473.70 M
|
$461.01 M
|
$402.32 M
|
$241.57 M
|
$179.19 M
|
$126.05 M
|
| Cost And Expenses |
$503.42 M
|
$472.85 M
|
$533.66 M
|
$505.43 M
|
$504.74 M
|
$482.98 M
|
$416.72 M
|
$247.81 M
|
$180.02 M
|
$126.05 M
|
| Interest Income |
$5.41 M
|
$7.08 M
|
$3.02 M
|
$509,000.00
|
$3.23 M
|
$10.25 M
|
$10.46 M
|
$4.10 M
|
$1.60 M
|
$929,000.00
|
| Interest Expense |
$49.60 M
|
$50.15 M
|
$37.12 M
|
$32.47 M
|
$22.43 M
|
$18.87 M
|
$22.40 M
|
$17.24 M
|
$5.40 M
|
$1.58 M
|
| Depreciation & Amortization |
$8.55 M
|
$7.87 M
|
$5.34 M
|
$6.21 M
|
$8.85 M
|
$4.78 M
|
$4.22 M
|
$3.59 M
|
$3.24 M
|
$1.83 M
|
| EBITDA |
$29.39 M |
-$92.08 M |
-$199.58 M |
-$202.87 M |
-$242.98 M |
-$332.26 M |
-$322.47 M |
-$428.29 M |
-$195.14 M |
-$128.71 M |
| EBITDA Ratio |
0.06
|
-0.23
|
-0.58
|
-0.64
|
-0.89
|
-1.81
|
-3.47
|
-5.34
|
-35.3
|
0
|
| Operating Income Ratio |
0.05
|
-0.18
|
-0.62
|
-0.65
|
-0.93
|
-1.65
|
-3.6
|
-11.97
|
-36.69
|
0
|
| Total Other Income/Expenses Net |
-$53.63 M
|
-$76.61 M
|
-$37.61 M
|
-$41.63 M
|
-$30.40 M
|
-$55.17 M
|
-$23.61 M
|
-$7.14 M
|
-$21.89 M
|
-$6.07 M
|
| Income Before Tax |
-$28.76 M
|
-$150.10 M
|
-$242.04 M
|
-$241.55 M
|
-$274.25 M
|
-$355.91 M
|
-$349.09 M
|
-$449.12 M
|
-$203.78 M
|
-$132.12 M
|
| Income Before Tax Ratio |
-0.05
|
-0.38
|
-0.74
|
-0.79
|
-1.05
|
-1.95
|
-3.83
|
-12.16
|
-41.1
|
0
|
| Income Tax Expense |
$27.35 M
|
$1.48 M
|
-$5.47 M
|
$8.91 M
|
$2.60 M
|
$478,000.00
|
-$94,000.00
|
-$165.12 M
|
-$3.74 M
|
$1.50 M
|
| Net Income |
-$56.11 M
|
-$151.58 M
|
-$236.57 M
|
-$250.46 M
|
-$276.85 M
|
-$356.39 M
|
-$349.00 M
|
-$284.00 M
|
-$200.04 M
|
-$132.12 M
|
| Net Income Ratio |
-0.11
|
-0.38
|
-0.72
|
-0.82
|
-1.06
|
-1.96
|
-3.82
|
-7.69
|
-40.35
|
0
|
| EPS |
-0.18 |
-0.51 |
-0.82 |
-0.92 |
-1.07 |
-1.48 |
-1.88 |
-1.85 |
-1.49 |
-1.2 |
| EPS Diluted |
-0.18 |
-0.51 |
-0.82 |
-0.92 |
-1.07 |
-1.48 |
-1.88 |
-1.85 |
-1.49 |
-1.2 |
| Weighted Average Shares Out |
$304.38 M
|
$295.16 M
|
$289.06 M
|
$271.42 M
|
$258.87 M
|
$240.42 M
|
$185.79 M
|
$153.36 M
|
$134.40 M
|
$109.92 M
|
| Weighted Average Shares Out Diluted |
$304.38 M
|
$295.16 M
|
$289.06 M
|
$271.42 M
|
$258.87 M
|
$240.42 M
|
$185.79 M
|
$153.36 M
|
$134.40 M
|
$109.92 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
